Barclays lowered the firm’s price target on MetLife (MET) to $95 from $96 and keeps an Overweight rating on the shares following the Q4 report.

In a report released today, Alex Scott from Barclays maintained a Buy rating on Metlife (MET – Research Report), with a price target of $95.00.

MetLife Inc. closed 6.04% below its 52-week high of $89.05, which the company achieved on November 27th.

Learn more about whether Erie Indemnity Company or MetLife, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Shares of MetLife (NYSE: NYSE:MET) fell 2% today after the company reported its fourth quarter earnings, which showed a mixed financial performance. While the insurer matched analyst estimates with ...

Khalaf announced key transactions aligned with the strategy, including the formation of Chariot Re, a Bermuda-based reinsurance company with a combined equity investment of over $1 billion, and the ...

MetLife (MET) delivered earnings and revenue surprises of -2.35% and 2.65%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

(Reuters) - MetLife (NYSE: MET) on Wednesday reported a rise in its fourth-quarter profit as it earned more in premiums and ...

(MET) on Wednesday reported fourth-quarter net income of $1.24 billion. On a per-share basis, the New York-based company said it had profit of $1.78.

The insurance industry is anticipated to have gained on rate hikes, strong retention rates, new business growth, an active ...